

Rachel Wong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4754055/publications.pdf>

Version: 2024-02-01

86
papers

4,713
citations

393982

19
h-index

102304

66
g-index

87
all docs

87
docs citations

87
times ranked

6366
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an Australian population. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, .	0.7	3
2	The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancer. <i>Hpb</i> , 2022, 24, 950-962.	0.1	3
3	Biology and Clinical Implications of Fecal Occult Blood Test Screen-Detected Colorectal Cancer. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	1
4	Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , .	0.7	0
5	Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2261-2272.	13.9	337
6	Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status. <i>Clinical Colorectal Cancer</i> , 2021, 20, e21-e34.	1.0	4
7	Prognostic significance of postsurgery circulating tumor <sc>DNA</sc> in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. <i>International Journal of Cancer</i> , 2021, 148, 1014-1026.	2.3	77
8	Metastectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. <i>Current Problems in Cancer</i> , 2021, 45, 100637.	1.0	11
9	Results of phase II trial of intensified neoadjuvant treatment with interdigitating radiotherapy and chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with locally advanced rectal cancer (PROARCT trial). <i>Radiotherapy and Oncology</i> , 2021, 155, 27-32.	0.3	5
10	Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. <i>Journal of Clinical Oncology</i> , 2021, 39, 966-977.	0.8	122
11	Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study. <i>Clinical Cancer Research</i> , 2021, 27, 2159-2167.	3.2	9
12	BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?. <i>Targeted Oncology</i> , 2021, 16, 227-236.	1.7	2
13	Cancer clinical trial vs <sc>real-world</sc> outcomes for standard of care <sc>first-line</sc> treatment in the advanced disease setting. <i>International Journal of Cancer</i> , 2021, 149, 409-419.	2.3	6
14	Bridging the gap: a pre-post feasibility study of embedding exercise therapy into a co-located cancer unit. <i>Supportive Care in Cancer</i> , 2021, 29, 6701-6711.	1.0	13
15	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003620.	3.9	88
16	Treatment and Outcomes of Oligometastatic Colorectal Cancer Limited to Lymph Node Metastases. <i>Clinical Colorectal Cancer</i> , 2021, , .	1.0	1
17	Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer. <i>Pharmacoeconomics</i> , 2021, 39, 953-964.	1.7	14
18	Stage dependent recurrence patterns and post-recurrence outcomes in non-metastatic colon cancer. <i>Acta Oncologica</i> , 2021, 60, 1106-1113.	0.8	5

#	ARTICLE	IF	CITATIONS
19	Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. <i>Current Problems in Cancer</i> , 2021, , 100793.	1.0	1
20	Characteristics and outcomes of participants in colorectal cancer biomarker trials versus a real-world cohort. <i>Acta Oncol</i> 3gica, 2021, 60, 482-490.	0.8	1
21	Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia. <i>Internal Medicine Journal</i> , 2020, 50, 165-172.	0.5	1
22	Dose modification for haematological toxicity: a survey of Australian medical oncologists. <i>Internal Medicine Journal</i> , 2020, 50, 1338-1343.	0.5	1
23	Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. <i>Pharmacoeconomics</i> , 2020, 38, 1263-1275.	1.7	3
24	Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia. <i>Internal Medicine Journal</i> , 2020, , .	0.5	2
25	Real world outcomes for neoadjuvant capecitabine versus infusional 5-Fluorouracil in the treatment of locally advanced rectal cancer. <i>Internal Medicine Journal</i> , 2020, 51, 1262-1268.	0.5	2
26	Resection of colorectal cancer liver metastases in older patients. <i>ANZ Journal of Surgery</i> , 2020, 90, 796-801.	0.3	7
27	Assessing real-world outcomes in metastatic colorectal cancer with KRAS G12C mutation.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16072-e16072.	0.8	2
28	Real-world survival outcomes of using neoadjuvant chemotherapy in pancreatic cancer patients: Findings from the PURPLE clinical registry.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16755-e16755.	0.8	2
29	Immunohistochemical evaluation of the prognostic and predictive power of epidermal growth factor receptor ligand levels in patients with metastatic colorectal cancer. <i>Growth Factors</i> , 2020, 38, 127-136.	0.5	0
30	European Society for Medical Oncology Invests in the Next Generation of Asia-Pacific Oncology Leaders. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 7-8.	0.1	0
31	Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. <i>JAMA Oncology</i> , 2019, 5, 1710.	3.4	383
32	The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. <i>International Journal of Cancer</i> , 2019, 145, 540-547.	2.3	15
33	Emerging strategies in the initial management of locally advanced rectal cancer. <i>Future Oncology</i> , 2019, 15, 2955-2965.	1.1	6
34	Body Composition Adjusted Dosing of Gemcitabine-Nab-Paclitaxel in Pancreatic Cancer Does Not Predict Toxicity Compared to Body Surface Area Dosing. <i>Nutrition and Cancer</i> , 2019, 71, 624-628.	0.9	10
35	Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 136-143.	0.7	12
36	Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?. <i>Internal Medicine Journal</i> , 2019, 49, 446-454.	0.5	12

#	ARTICLE	IF	CITATIONS
37	Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. <i>Future Oncology</i> , 2019, 15, 567-577.	1.1	20
38	Squamous cell carcinoma of unknown primary masquerading as multiple splenic abscesses. <i>ANZ Journal of Surgery</i> , 2019, 89, 606-607.	0.3	0
39	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , 2019, 68, 663-671.	6.1	234
40	How accurate are medical oncologists' impressions of management of metastatic colorectal cancer in Australia?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e167-e174.	0.7	0
41	The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. <i>Acta Oncologica</i> , 2018, 57, 1438-1444.	0.8	78
42	Mismatch repair deficiency assessment by immunohistochemistry: for Lynch syndrome screening and beyond. <i>Future Oncology</i> , 2018, 14, 2725-2739.	1.1	14
43	Stage-based Variation in the Effect of Primary Tumor Side on All Stages of Colorectal Cancer Recurrence and Survival. <i>Clinical Colorectal Cancer</i> , 2018, 17, e569-e577.	1.0	23
44	Previous Bevacizumab and Efficacy of Later Anti-epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry. <i>Clinical Colorectal Cancer</i> , 2018, 17, e593-e599.	1.0	6
45	Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3516-3516.	0.8	19
46	Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2017, 16, e45-e54.	1.0	9
47	The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 314-321.	0.7	7
48	Left versus right sided colorectal cancer: Teasing out drivers of disparity in outcomes in metastatic disease.. <i>Journal of Clinical Oncology</i> , 2017, 35, 682-682.	0.8	1
49	Treatment sequencing and outcomes in synchronous metastatic rectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 750-750.	0.8	1
50	Examining progression-free survival in first- and second-line treatment for BRAF-mutant metastatic colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 728-728.	0.8	0
51	Small bowel adenocarcinoma treatment: A single centre experience.. <i>Journal of Clinical Oncology</i> , 2017, 35, 451-451.	0.8	0
52	Utilization of systemic therapy options in the routine treatment of metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 738-738.	0.8	0
53	Impact of clinical and molecular features on risk of recurrence following curative intent resection of metastases in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 785-785.	0.8	67
54	Survival impact of the Australian National Bowel Cancer Screening Programme. <i>Internal Medicine Journal</i> , 2016, 46, 166-171.	0.5	22

#	ARTICLE	IF	CITATIONS
55	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. <i>Science Translational Medicine</i> , 2016, 8, 346ra92.	5.8	1,036
56	Impact of Surgical Complications Following Resection of Locally Advanced Rectal Adenocarcinoma on Adjuvant Chemotherapy Delivery and Survival Outcomes. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 916-924.	0.7	16
57	Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016, 15, e9-e15.	1.0	45
58	Primary Tumor Resection and Overall Survival in Patients With Metastatic Colorectal Cancer Treated With Palliative Intent. <i>Clinical Colorectal Cancer</i> , 2016, 15, e125-e132.	1.0	8
59	The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3511-3511.	0.8	5
60	Serial circulating tumor DNA (ctDNA) and recurrence risk in patients (pts) with resectable colorectal liver metastasis (CLM).. <i>Journal of Clinical Oncology</i> , 2016, 34, e15131-e15131.	0.8	12
61	Impact of anti-VEGF therapy in metastatic colorectal cancer with an intact primary tumour.. <i>Journal of Clinical Oncology</i> , 2016, 34, 650-650.	0.8	2
62	Use and impact of bevacizumab in patients undergoing liver resection for metastatic colorectal cancer in routine clinical practice.. <i>Journal of Clinical Oncology</i> , 2016, 34, 698-698.	0.8	0
63	Use and impact of selective internal radiation therapy (SIRT) in routine care patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 742-742.	0.8	0
64	A phase II study of oxaliplatin/5FU/bevacizumab and concurrent pelvic radiation in patients with simultaneous primary and metastatic rectal cancer: The Chrome-B trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3613-3613.	0.8	0
65	Less Surgery, Improved Survival From Stage IV Colorectal Cancer?. <i>JAMA Surgery</i> , 2015, 150, 818.	2.2	0
66	Treatment and outcomes of metastatic colorectal cancer in <sc>A</sc>ustralia: defining differences between public and private practice. <i>Internal Medicine Journal</i> , 2015, 45, 267-274.	0.5	18
67	Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in <sc>A</sc>ustralia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, 262-271.	0.7	6
68	Treatment of metastatic colorectal cancer: focus on panitumumab. <i>Cancer Management and Research</i> , 2015, 7, 189.	0.9	14
69	Multidisciplinary Management of Locally Advanced Rectal Cancer—An Evolving Landscape?. <i>Clinical Colorectal Cancer</i> , 2015, 14, 251-261.	1.0	21
70	Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015, 26, 1715-1722.	0.6	517
71	Patterns of care and outcomes for elderly patients with metastatic colorectal cancer in Australia. <i>Journal of Geriatric Oncology</i> , 2015, 6, 387-394.	0.5	20
72	Impact of primary tumor stage on survival following resection of metachronous liver and/or lung metastases in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3557-3557.	0.8	1

#	ARTICLE	IF	CITATIONS
73	Association between type 2 diabetes mellitus (T2DM), diabetic therapies and clinical outcomes in patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, e14637-e14637.	0.8	0
74	Clinicopathological characteristics and outcomes of young patients (YP) with metastatic colorectal cancer (mCRC) in Australia.. Journal of Clinical Oncology, 2015, 33, e14648-e14648.	0.8	0
75	ASPECCT: panitumumab versus cetuximab for colorectal cancer. Lancet Oncology, The, 2014, 15, e302-e303.	5.1	0
76	Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Annals of Oncology, 2013, 24, 1253-1261.	0.6	76
77	Re: The developing clinical problem of chemotherapy-induced hepatic injury. ANZ Journal of Surgery, 2012, 82, 569-569.	0.3	0
78	Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C). Journal of Clinical Oncology, 2012, 30, 1620-1627.	0.8	357
79	The impact of TP53 mutation on high-risk rectal cancer patients treated within the EXPERT-C trial, a randomized phase II study of neoadjuvant oxaliplatin/capecitabine (CAPOX) and chemoradiation (CRT) with or without cetuximab.. Journal of Clinical Oncology, 2012, 30, e14088-e14088.	0.8	0
80	Guidelines for the management of oesophageal and gastric cancer. Gut, 2011, 60, 1449-1472.	6.1	570
81	A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Annals of Oncology, 2011, 22, 2042-2048.	0.6	197
82	Optimising treatment regimens for the management of advanced gastric cancer. Annals of Oncology, 2009, 20, 605-608.	0.6	16
83	What is the impact of biologicals in colorectal cancer?. Targeted Oncology, 2008, 3, 59-69.	1.7	0
84	CLINICIANS'™ ATTITUDES TOWARDS MANAGEMENT OF METASTATIC COLORECTAL ADENOCARCINOMA. ANZ Journal of Surgery, 2008, 78, 454-460.	0.3	4
85	Using Predictive Biomarkers to Select Patients With Advanced Colorectal Cancer for Treatment With Epidermal Growth Factor Receptor Antibodies. Journal of Clinical Oncology, 2008, 26, 5668-5670.	0.8	83
86	Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet, The, 2007, 369, 1923-1924.	6.3	27